Collegium Pharmaceuticals Inc., a Cumberland-based developer of late-stage drugs that add market value and clinical benefit to existing products, has raised $5.5 million in Series C funding, according to a regulatory filing.
Backers include Boston Millennia Partners and Westfield Capital Management.
Beyond Cash Donations: How New Forms of Giving Are Transforming Not-for-Profit Accounting
Evolving Funding Landscape for Not-for-Profits Not-for-profit organizations are being asked to do more with less,…
Learn More
Collegium is a privately held company that focuses on uses for pharmaceuticals already on the market, many of which are coming off patent. It was founded in 2002, by a group of senior pharmaceutical executives.
“We believe that large market opportunities exist in the development of product improvements and line extensions strategies, all protected by strong intellectual property,” they say on the company’s Web site.
Additional information about Collegium Pharmaceuticals Inc., and the products it has launched, is available at www.collegiumpharma.com.
